Results 211 to 220 of about 3,997,149 (388)

Effect of interdisciplinary obesity care on metabolic markers and body weight in people with type 2 diabetes in a rural setting: A randomised controlled trial

open access: yesClinical Obesity, Volume 15, Issue 2, April 2025.
Summary Management of type 2 diabetes includes medications that can unintentionally increase obesity and insulin resistance. This unblinded, single‐centre, randomised controlled trial focused on rural Australian adults with type 2 diabetes (aged 18–75 and body mass index [BMI] >30 kg/m2), measuring the effectiveness of a tailored interdisciplinary ...
Giuliana O. Murfet   +3 more
wiley   +1 more source

Diving with hypertension and antihypertensive drugs

open access: green, 2020
Peter E. Westerweel   +5 more
openalex   +2 more sources

Author response for "Genetic risk of hyperuricemia in hypertensive patients associated with antihypertensive drug therapy: a longitudinal study"

open access: gold, 2021
Yu Chen   +11 more
openalex   +1 more source

Cluster analysis of angiotensin biomarkers to identify antihypertensive drug treatment in population studies. [PDF]

open access: yesBMC Med Res Methodol, 2023
Arisido MW   +13 more
europepmc   +1 more source

Progression of albumin/creatinine ratio (ACR) and estimated glomerular filtration rate (eGFR) over 24 years in people with type 2 diabetes. Drivers, potential protectors and associated mortality

open access: yesDiabetic Medicine, EarlyView.
Abstract Introduction The pathophysiology of chronic kidney disease (CKD) and type 2 diabetes (T2D) is multifactorial and associated with a plethora of underlying conditions and complications. Their link is reciprocal and understanding its nature, particularly over time, could improve the health of many.
Andreas Matheou   +13 more
wiley   +1 more source

Antihypertensive medications and hepatocellular carcinoma risk: a systematic review

open access: yesJournal of Current Oncology and Medical Sciences
Introduction: Emerging evidence suggests that antihypertensive medications may influence the risk, progression, and survival outcomes of hepatocellular carcinoma (HCC). However, findings across studies remain inconsistent.
Shadman Newaz   +8 more
doaj  

Home - About - Disclaimer - Privacy